Amicus Therapeutics, Inc. (NASDAQ:FOLD)

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s Financial Overview

Amicus Therapeutics, Inc. (NASDAQ:FOLD) declined -8.14% yesterday to close its trading session at $5.98. The company has 1 year Price Target of $12.38. Amicus Therapeutics, Inc. has 52-Week high of $10.8 and 52-Week Low of $4.98. The stock touched its 52-Week High on Dec 3, 2015 and 52-Week Low on Jun 27, 2016. The stock traded with the volume of 6.86 Million shares yesterday. The firm shows the market capitalization of $851.13 Million.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.33/share against the analyst consensus estimate of $-0.32/share. The difference between the actual and expected EPS is $-0.01 a share with a surprise factor of -3.1%.

The firm is trading with SMA20 of -26.77 Percent, SMA50 of -22.61 Percent and SMA200 of -16.2 percent. Amicus Therapeutics, Inc. has P/S value of 405.3 while its P/B value stands at 2.5. Similarly, the company has Return on Assets of -20.5 percent, Return on Equity of -55.4 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 83.8 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Amicus Therapeutics, Inc. (NASDAQ:FOLD). On 18-May-16 BofA/Merrill Initiated Amicus Therapeutics, Inc. Stock  to Buy. Another firm also rated the stock on 14-Apr-16 where Robert W. Baird Initiated the stock to Neutral.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 8 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 12.00, with a high estimate of 17.00 and a low estimate of 9.00. The median estimate represents a +100.67% increase from the last price of 5.98.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

TripAdvisor Inc. (NASDAQ:TRIP)

TripAdvisor Inc. is an online travel research company. The Company features reviews and advice on hotels, resorts, flights, vacation rentals, vacation packages, travel guides, and lots more. The sites operate in many countries worldwide, including China under daodao.com. TripAdvisor Inc. is headquartered in Newton, Massachusetts.

TripAdvisor Inc. (NASDAQ:TRIP)’s Financial Outlook

The 20 analysts offering 12-month price forecasts for TripAdvisor Inc have a median target of 56.00, with a high estimate of 70.00 and a low estimate of 41.00. The median estimate represents a +15.99% increase from the last price of 48.28.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, TripAdvisor Inc. has a Consensus Recommendation of 3.06. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -2.07% and closed its last trading session at $48.28. The company has the market capitalization of $7.03 Billion. The stock has 52-week high of $87.5 and 52-Week low of $48.25. The firm touched its 52-Week high on Dec 16, 2015 and 52-Week low on Nov 14, 2016. The company has volume of 2.7 Million shares. The company has a total of 145.7 Million shares outstanding.

TripAdvisor Inc. (NASDAQ:TRIP) in the last quarter reported its actual EPS of $0.53/share where the analyst estimated EPS was $0.52/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 1.9 percent.

The company has YTD performance of -43.37 percent. Beta for TripAdvisor Inc. stands at 2.15 while its ATR (average true range) is 1.79. The company has Weekly Volatility of 2.27%% and Monthly Volatility of 3.25%%.

TripAdvisor Inc. has distance from 20-day Simple Moving Average (SMA20) of -11.32%, Distance from 50-Day Simple Moving Average of -18.98 percent and Distance from 200-Day Simple Moving Average of -23.77%.

The Company currently has ROA (Return on Assets) of 5.3 percent, Return on Equity (ROE) of 8 Percent and Return on Investment (ROI) of 13.1% with Gross margin of 95.5 percent and Operating & Profit margin of 9.1% and 8.1% respectively.